Operating Lease, Right-of-Use Asset of Lineage Cell Therapeutics, Inc. from 31 Mar 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Lineage Cell Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 31 Dec 2025.
  • Lineage Cell Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 31 Dec 2025 was $2,131,000, a 0.61% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Lineage Cell Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $2,131,000 -$13,000 -0.61% 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q3 2025 $2,311,000 -$51,000 -2.2% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $1,817,000 -$767,000 -30% 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $1,904,000 -$951,000 -33% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $2,144,000 -$378,000 -15% 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q3 2024 $2,362,000 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $2,584,000 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $2,855,000 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $2,522,000 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q4 2020 $215,000 -$560,000 -72% 31 Dec 2020 10-K 11 Mar 2021 2020 FY
Q4 2019 $775,000 31 Dec 2019 10-K 11 Mar 2021 2020 FY
Q3 2019 $4,950,000 30 Sep 2019 10-Q 12 Nov 2019 2019 Q3
Q2 2019 $4,554,000 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 $4,678,000 31 Mar 2019 10-Q 09 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.